AXIS 1 "RESEARCH, TECHNOLOGICAL DEVELOPMENT AND INNOVATION ACTION 1.1.4 “Support for collaborative R&D activities for the development of new sustainable technologies, products and services”
PRELIMINARY EFFICACY STUDY OF A FOOD SUPPLEMENT TO SUPPORT NCGS (Non-celiac gluten sensitivity) AND COELIAC DISEASE
Design and manufacture of a food supplement containing a plant enzyme and a probiotic. Study of the plant enzyme's proteolytic activity against gluten and the anti-inflammatory activity of the combination of active ingredients. Development of the finished product to improve its stability in terms of the viability of the probiotic strain.
Intervention realised with funding POR FESR 2014-2020 (Objective: '"Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 79.150.
PRODUCTION AND CHARACTERISATION OF AN AMARANTH EXTRACT FOR CARDIOVASCULAR HEALTH
Investigation and development of a food alternative with a health-promoting effect on the cardiovascular system. Field and vertical cultivations of different varieties of Amaranthus caudatus, production and characterisation of fluid extracts and simultaneous evaluation of biological activity.
Intervention realised with funding POR FESR 2014-2020 (Objective: "Increasing business innovation activity").
Intervention carried out with the benefit of a grant from Regione Veneto amounting to euro 35.375.
Thanks to the Regione Veneto and the European Union, Labomar has obtained important funding for the development of botanical extracts and food supplements to support health.
The precise study of products and the acquisition of new skills will enable Labomar to make important improvements in the production, proposition and positioning of its products.
Our focus is always on improving the entire production chain, services and the continuous raising of our quality standards, so that we can also address the most important international brands.
“Certified B Corporation” is a trademark licensed by B Lab, a private non-profit organization, to companies like ours that have successfully completed the B Impact Assessment (“BIA”) and therefore meet the requirements set by B Lab for social and environmental performance, accountability, and transparency. It is specified that B Lab is not a conformity assessment body as defined by Regulation (EU) No 765/2008, nor is it a national, European, or international standardization body as per Regulation (EU) No 1025/2012. The criteria of the BIA are distinct and independent from the harmonized standards resulting from ISO norms or other standardization bodies, and they are not ratified by national or European public institutions.
Platform Patents
Sublingual Delivery
NANOEMULSION DELIVERY SYSTEM – PCT IB2009/055754
A nanoemulsion, which acts as delivery system, consisting of a pool of excipients specifically selected to:
solubilise lipophilic molecules, insoluble in aqueous solutions.
improve bioavailability of otherwise poorly absorbable molecules.
increase the speed of action of the product.
Dosage form: sublingual oral spray.
the high vascularisation of the sublingual mucosa allows faster absorption.
intestinal absorption is bypassed, thereby avoiding first-pass effect in the hepatic circulati.
Deliverable active ingredients: poorly bioavailable lipophilic substances, metabolised in the liver.
Examples of application:
sublingual spray with vitamin D3, known to contribute to calcium homeostasis and to maintain bone physiological wellbeing.
sublingual spray with melatonin, useful for alleviating sleep disorders (jet lag, insomnia).
Entric Delivery
ENTEROSOMA – EPO 13723129.6
Pool of excipients contained in gastro-resistant tablets designed to bypass the physiological constraints to intestinal absorption due to:
thickness of mucous secretions.
cytochrome activity.
P-glycoprotein action.
proteolytic hydrolysis.
low transmucosal flux through tight junctions.
Dosage form: gastro-resistant tablets.
Deliverable active ingredients: raw materials with poor bioavailability in the intestines.
Examples of application:
formulation in gastro-resistant tablets to deliver berberine, useful for controlling blood sugar levels and cholesterol.
formulation in gastro-resistant tablets with curcumin, dry extract with marked anti-inflammatory properties.
PROBUP DROPS™ – Patent pending 102023000026925
Compositions improving probiotics-in-oil’s dispersions.
A pool of substances that stabilizes the product, reducing the formation of aggregates and facilitating the resuspension of probiotics once the liquid is shaken.
Dosage form:Oil drops.The new technology resolves the typical Challenges of probiotic oil drops development:
Critical organoleptic stability through the Screening to select best ingredients combo for the specific strain(s)
Additives are compliant with Infant food regulation
Clean label thanks to a short ingredient list and natural components.
Advantages:
Shorter Development Time & Increased Project Success
Easier re-suspendable sediment
Topical application
HYDRALAYER™ – patent pending
HYDRALAYER™ is a biomimetic Patented technology for all your topical needs:
emulsion characterized by a particular “active” structure: indeed, its multilamellar organization (liquid crystals) reminds the stratum corneum lipid structure.
more dermocompatible than a traditional emulsion, thanks to its biomimetic structure.
a basic moisturizing cream, suitable for many applications, for sensitive and normal skin.
100% ingredients of natural origin, capable of moisturizing the skin and keeping it hydrated over time.
dermatologically tested for sensitive skin.
8 metal tested (Ni, Cr, Co, Hg, As, Cd, Pb, Sb).
Allergen free.
In vitro and in vivo tested.
By adding different active ingredients, this platform formulation can develop different functional products:
